Skip to main content
Premium Trial:

Request an Annual Quote

ABI Settles Outstanding Legal Disputes with Promega

This article has been updated from a previous version, which reported that Applied Biosystems had settled a legal dispute with Promega related to PCR technology.
NEW YORK (GenomeWeb News) – Applied Biosystems said today that it has settled outstanding legal disputes with Promega.
A company spokeswoman said that the dispute was related to the sale of forensic identification and paternity testing kits.  
Exact terms of the settlement were not disclosed.
Promega filed the suit against ABI and several other defendants, including Lifecodes, Cellmark Diagnostics, and Genomics International, in 2001. The suit alleged that these defendents infringed US Patent Nos. 6,221,598 and 5,843,660 by selling forensic identification and paternity testing kits.  
The agreement follows the fall 2005 settlement of a legal dispute between ABI and Promega. Promega settled with Roche separately around the same time. The settlements opened the door for Promega to negotiate a license to Roche’s PCR patents with ABI.
ABI has settled a number of legal disputes in the past year, but still has some outstanding cases, including a patent infringement suit filed by Thermo Electron unit Thermo Finnigan, a patent infringement suit related to labeled and modified nucleotides filed by Enzo Biochem and Yale University, and a class action suit filed by Molecular Diagnostics Laboratories for alleged anticompetitive practices in selling Taq polymerase.
ABI has settled four cases since the settlement with Promega in Sept. 2005, according to BioCommerce Week, a GenomeWeb Daily News sister publication.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.